Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
Ilonka Rohm1, Daniel Kretzschmar1, Rudin Pistulli1
1Department of Internal Medicine I, Friedrich-Schiller-University of Jena, Jena, Germany.
Insights
Ivabradine therapy improved chronic heart failure (CHF) symptoms and ejection fraction by reducing systemic inflammation and restoring dendritic cell levels in patients. This study highlights ivabradine's anti-inflammatory potential beyond heart rate reduction.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Inflammation is a key factor in chronic heart failure (CHF) progression.
- Ivabradine is recognized for reducing morbidity and mortality in CHF patients.
- Potential anti-inflammatory effects of ivabradine in CHF remain under-explored.
Purpose of the Study:
- To investigate the impact of ivabradine on systemic inflammation in patients with CHF.
- To explore potential anti-inflammatory mechanisms of ivabradine beyond heart rate reduction.
Main Methods:
- 33 patients with CHF received ivabradine treatment per ESC guidelines.
- Circulating dendritic cells and inflammatory mediators were analyzed using FACS and ELISA.
- Measurements were taken before and during ivabradine therapy.
Main Results:
- Ivabradine treatment significantly improved CHF symptoms and left ventricular ejection fraction.
- Serum levels of tumor necrosis factor-alpha (TNF-α) were significantly reduced.
- A reconstitution of circulating dendritic cells, typically reduced in CHF, was observed.
Conclusions:
- Ivabradine treatment in CHF patients led to improved heart failure symptoms and ejection fraction.
- Ivabradine demonstrated a normalization of inflammatory mediators, including TNF-α.
- The study suggests ivabradine possesses beneficial anti-inflammatory properties in CHF management.
Abstract:
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions. Beyond the reduction of heart rate, only limited knowledge exists about potential anti-inflammatory effects of ivabradine that might contribute to its benefit in CHF. Thus, the present study aimed to investigate the effect of ivabradine on systemic inflammation. Methods. In the present study, 33 patients with CHF due to dilated, ischemic, and hypertensive cardiomyopathy were treated with ivabradine according to the guidelines of the European Society of Cardiology (ESC). A number of circulating dendritic cells as well as inflammatory mediators were investigated using FACS analysis and ELISA, respectively, before and during ivabradine therapy. Results. Treatment with ivabradine resulted in a significant improvement of CHF symptoms as well as an increase in left ventricular ejection fraction. Moreover, ivabradine treatment led to a significant reduction of TNF-alpha (TNF-α) serum levels and a reconstitution of circulating dendritic cells which are known to be reduced in patients with CHF. Conclusion. We show that treatment with ivabradine in patients with CHF resulted in an improvement of HF symptoms and ejection fraction as well as a normalization of inflammatory mediators.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure III: Clinical Manifestations
01:22Heart Failure VI: Adjunct Therapies
01:29Heart Failure II: Pathophysiology